Supply of betamethasone (as valerate) (CELESTONE-M) 0.2mg/g cream tube by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, provides the legal framework for regulating therapeutic goods in Australia, addressing the need for a comprehensive system to ensure the safety, quality, and efficacy of such goods. The Act aims to protect public health by controlling the manufacture, importation, supply, and advertising of therapeutic goods. In a specific instance under this Act, on January 24, 2013, the delegate of the Secretary of the Department of Health and Ageing authorised the supply of betamethasone (as valerate) (CELESTONE-M) 0.2 mg/g cream tube, which did not conform to certain labelling requirements. This consent was granted under sections 14 and 14A of the Act and was subject to specific conditions, including the retention of existing labels bearing the previous sponsor’s details and the implementation of arrangements for handling any complaints or queries regarding the product. This action underscores the Act’s objective to maintain stringent controls while balancing the need for flexibility in certain circumstances to facilitate the availability of necessary therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, applies to the regulation and administration of therapeutic goods in Australia, including medicines, medical devices, and other health-related products. The Act encompasses a broad range of persons and entities involved in the manufacturing, supply, advertising, and importation of these goods, ensuring they meet safety, quality, and efficacy standards. The Act extends to the entire Commonwealth of Australia, thereby covering all states and territories. However, certain products and activities may be exempt or subject to specific thresholds, such as low-risk medical devices or small-scale manufacturing. The Act also allows for the delegation of certain powers to subordinate instruments, which can extend or restrict its application in particular contexts. In this instance, the Act was invoked to address a specific issue with the labelling of betamethasone (as valerate) (CELESTONE-M) 0.2 mg/g cream tube, where the details of the previous sponsor were listed instead of the current supplier's information. The delegate of the Secretary granted consent for the supply of specified batches of the product under certain conditions, ensuring compliance and consumer safety.

Key Provisions

The Therapeutic Goods Act 1989 (section 14 and 14A) allows the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of specific therapeutic goods that do not fully comply with the regulatory requirements. In this case, the consent was granted for the supply of betamethasone (as valerate) (CELESTONE-M) 0.2 mg/g cream tube [Aust R 18778] by Merck Sharp & Dohme Australia Pty Ltd (the Company). The product in question does not comply with paragraph 3(2)(l) of Therapeutic Goods Order 69, specifically the requirement that the sponsor’s details must appear on the carton and tube labels. Instead, the details of the previous sponsor, Schering-Plough Pty Ltd, are listed. The consent provided is limited to specific batches (2028, 2030, and 2031) of the product, and it applies only to the currently used labels with the previous sponsor's details. No other changes have been made to the product, and arrangements are in place to ensure that any complaints or queries about these products will be promptly addressed. Under the Therapeutic Goods Act 1989, the delegate of the Secretary has certain obligations and requirements when granting such consent. The consent must be subject to specific conditions that ensure the therapeutic goods are safe and of acceptable quality. In this instance, the consent is conditional on the fact that the product in question pertains to particular batches and labels only, and that there are mechanisms to handle any complaints or queries effectively. Additionally, the consent ensures that the supply of the non-compliant product is limited in scope and does not lead to broader regulatory issues. Breach of the conditions stipulated in the Therapeutic Goods Act 1989 can result in both civil and criminal consequences. While the specific penalties are not detailed in the provided text, generally, non-compliance with the Act can lead to fines, imprisonment, or both. The exact penalties depend on the severity and nature of the breach. In this specific case, failure to adhere to the conditions of the consent could result in the revocation of the consent, potential fines, or other enforcement actions by regulatory authorities to ensure compliance with the Act.